British journal of cancer · 2026
Overall survival according to timing of immune checkpoint inhibitors administration in patients with advanced cancer: results from a large single-centre cohort analysis.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Bosetti Tommaso, Kennedy Oliver John, Califano Raffaele, Waddell Tom, Metcalf Rob, Kreft Sophia, Lee Rebecca, Lorigan Paul
Аннотация
BACKGROUND: Immune checkpoint inhibitors (ICIs) have revolutionised cancer treatment. Previous studies suggested that early time-of-day administration is associated with better outcomes. We performed a retrospective study in patients treated at a large tertiary cancer centre.
METHODS: Patients receiving ICIs between January 2018 and December 2023 were grouped according to whether they had ≥50% ("late group") or <50% ("early group") of cycles after the median time of all treatments. The endpoint was overall survival (OS). Hazard ratios (HRs) were estimated using Cox models with and without time-dependent variables.
RESULTS: 2631 patients with advanced/metastatic lung cancer (45%), melanoma (23%), renal carcinoma (18%), head and neck (9%), and urothelial cancer (5%) were included. Median age was 68.2 years and median infusion time was 12:49 h. At a median follow-up of 32 months, median OS was 13.1 (95% CI 11.8-14.4) vs 21.4 (19.8-24.5) months for late and early group. Late group was associated with shorter OS on both the standard analysis (HR 1.48, 1.33-1.63) and the time-dependent model (HR 1.30, 1.16-1.44).
CONCLUSIONS: This study provides further evidence in favour of early ICIs administration with a large sample size and a time-dependent model, which reduces the risk of immortal time bias. Data from randomised trials are required to confirm these findings.
METHODS: Patients receiving ICIs between January 2018 and December 2023 were grouped according to whether they had ≥50% ("late group") or <50% ("early group") of cycles after the median time of all treatments. The endpoint was overall survival (OS). Hazard ratios (HRs) were estimated using Cox models with and without time-dependent variables.
RESULTS: 2631 patients with advanced/metastatic lung cancer (45%), melanoma (23%), renal carcinoma (18%), head and neck (9%), and urothelial cancer (5%) were included. Median age was 68.2 years and median infusion time was 12:49 h. At a median follow-up of 32 months, median OS was 13.1 (95% CI 11.8-14.4) vs 21.4 (19.8-24.5) months for late and early group. Late group was associated with shorter OS on both the standard analysis (HR 1.48, 1.33-1.63) and the time-dependent model (HR 1.30, 1.16-1.44).
CONCLUSIONS: This study provides further evidence in favour of early ICIs administration with a large sample size and a time-dependent model, which reduces the risk of immortal time bias. Data from randomised trials are required to confirm these findings.